DNLI Stock Forecast: Denali Therapeutics, Inc. Price Predictions for 2026-2027
The 21 Wall Street analysts covering Denali Therapeutics, Inc. hold a median 12-month price target of $35 — +89.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 61 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Denali Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (80): Analysts have, on balance, been raising their forecasts.
Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
DNLI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DNLI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +89.7% from it.
Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Morgan Stanley | Maintains | Overweight | $42 → $37 |
| 13 Nov 2026 | Wells Fargo | Initiates | Overweight | $35 |
| 4 Nov 2026 | BTIG | Reiterates | Buy | $39 |
| 4 Nov 2026 | Morgan Stanley | Maintains | Overweight | $40 → $42 |
| 4 Nov 2026 | Wedbush | Maintains | Outperform | $23 → $24 |
| 25 Aug 2026 | B. Riley Securities | Maintains | Buy | $30 → $35 |
| 7 Aug 2026 | UBS | Maintains | Buy | $25 → $34 |
| 23 July 2026 | Morgan Stanley | Maintains | Overweight | $35 → $36 |
| 16 July 2026 | Deutsche Bank | Maintains | Buy | $31 → $35 |
| 13 July 2026 | JP Morgan | Reinstates | Overweight | $29 |
| 26 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 14 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 11 May 2026 | BTIG | Reiterates | Buy | — |
| 8 May 2026 | Wedbush | Maintains | Outperform | — |
| 22 Apr 2026 | Leerink Partners | Maintains | Outperform | — |
| 7 Apr 2026 | Baird | Maintains | Outperform | — |
| 26 Mar 2026 | Baird | Maintains | Outperform | — |
| 26 Mar 2026 | Goldman Sachs | Maintains | Buy | — |
| 26 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Mar 2026 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DNLI.
This page is one stock. Monday covers all of them.
DNLI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
DNLI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Denali Therapeutics, Inc. returned +7.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
DNLI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 140.3×
- Price / book
- 3.2×
- EV / EBITDA
- —
Cheaper than 3% of US stocks
Cheaper than 29% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 97.4%
- Operating margin
- —
- Net margin
- —
Higher than 99% of US stocks
- Return on equity
- −33.9%
- Return on assets
- −28.7%
- Dividend yield
- —
Higher than 27% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Denali Therapeutics, Inc. has a market value of $2.9B and an enterprise value of $2.4B.
Revenue in the twelve months to 30 June 2026: $3.6M.
Net income over the same four quarters: −$511.5M, a −14191.2% net margin.
Diluted earnings per share, trailing twelve months: −$2.84.
Free cash flow in the twelve months to 30 June 2026: −$466.3M.
Denali Therapeutics, Inc. employs 503 people — $7K of revenue per employee.
Data provided by Twelve Data
DNLI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at DNLI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Denali Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about DNLI
What is the DNLI stock price forecast for 2026-2027?
The 21 Wall Street analysts covering Denali Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $24 to $46. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is DNLI stock a buy right now?
Of the 21 analysts covering Denali Therapeutics, Inc., 20 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Denali Therapeutics, Inc. 61 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank DNLI?
As at 21 Nov 2026, Denali Therapeutics, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (80 of 100).
Will DNLI stock go up?
No one can know that. What the data says: the median 12-month target from 21 analysts implies +89.7% from the last close, and Ticker Nerd's factor model ranks Denali Therapeutics, Inc. 61 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the DNLI stock forecast for 2030?
No analyst covering Denali Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DNLI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $46 over the next 12 months.
How has DNLI stock performed over the past year?
Denali Therapeutics, Inc. returned +7.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Denali Therapeutics, Inc. do?
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines for serious neurodegenerative and lysosomal storage diseases. Denali Therapeutics advances a portfolio of therapeutic programs aimed at conditions such as Alzheimer's disease, Parkinson's disease, and other rare neurological disorders.
About Denali Therapeutics, Inc.
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines for serious neurodegenerative and lysosomal storage diseases. Denali Therapeutics advances a portfolio of therapeutic programs aimed at conditions such as Alzheimer's disease, Parkinson's disease, and other rare neurological disorders. The company’s approach centers on delivering biologic and genetic medicines across the blood-brain barrier through its proprietary TransportVehicle platform, which is designed to improve access to hard-to-reach tissues in the central nervous system. Denali Therapeutics also works on product candidates across enzyme, oligonucleotide, and antibody-based programs, supporting a broader pipeline that targets both brain and body diseases. Headquartered in South San Francisco, California, Denali Therapeutics operates within the biotechnology sector and plays a role in the development of next-generation therapies for complex, high-unmet-need conditions.
CEO Dr. Ryan J. Watts Ph.D. · 503 employees · United States · https://www.denalitherapeutics.com